NGR peptide-modified exosomes delivering resveratrol reprogrammed immunosuppressive myeloid cells, restored anti-tumor T cell activity, and significantly reduced liver cancer tumors in mice.
Immune reprogrammingNGR-guided exosomes converted immunosuppressive MDSCs into an anti-tumor state, enabling CD8+ T cell killing activity
What the researchers found
NGR-peptide-modified exosomes loaded with resveratrol achieved 19.3% drug encapsulation efficiency, targeted tumor MDSCs, downregulated CXCR2/NF-κB signaling, and significantly reduced tumor volume while boosting CD8+ T cell activity in a liver cancer model.
Why it matters
Immunotherapy resistance is often driven by immunosuppressive cells in the tumor. This peptide-guided exosome platform offers a way to reverse that suppression and restore anti-tumor immunity.
How the study worked
Network pharmacology, single-cell RNA-seq analysis, generation of CAF-derived NGR-modified exosomes, in vitro MDSC/T cell co-culture assays, and in vivo murine liver cancer xenograft model.
What this study cannot tell us
Mouse xenograft model only. Exosome manufacturing scalability is challenging. Long-term safety of CAF-derived exosomes unknown. Applicability to other cancer types not tested.
How to read the evidence
Comprehensive preclinical study with multi-omics analysis and in vivo validation. Novel platform but early-stage.
When this study was published
Published in 2025.
The bigger picture
This represents a convergence of peptide targeting, exosome biology, and tumor immunology — using a peptide to guide a biological delivery vehicle that reprograms the immune environment against cancer.
Questions still open
- Can this NGR-exosome platform be adapted for other cancer types?
- How does this compare to checkpoint inhibitor immunotherapy?
- What are the manufacturing challenges for clinical-grade peptide-modified exosomes?
Common questions
How does a peptide help fight cancer here?
What are exosomes?
Read the original research
NGR-modified cancer-associated fibroblast-derived exosomes deliver resveratrol to inhibit CXCR2/NF-κB signaling in myeloid-derived suppressor cells and reverse immune suppression in liver cancer.
International immunopharmacology, 174, 116326
Citation
Ding, Lijuan; Wang, Qiang; Wang, Xue; Fu, Weijia; Deng, Chen; Wang, Shudong. (2026). NGR-modified cancer-associated fibroblast-derived exosomes deliver resveratrol to inhibit CXCR2/NF-κB signaling in myeloid-derived suppressor cells and reverse immune suppression in liver cancer.. International immunopharmacology, 174, 116326. https://doi.org/10.1016/j.intimp.2026.116326